Rainer Strohmenger
Directeur/Membre du Conseil chez AMBOSS GmbH
Profil
Rainer Strohmenger is currently a Non-Executive Director at Quanta Dialysis Technologies Ltd.
and a Director at AMBOSS GmbH.
He previously held positions as a Managing Partner at Wellington Partners GmbH and a Member-Supervisory Board at iOmx Therapeutics AG.
In his former roles, he served as an Independent Director at Oxford Immunotec Global Ltd., a Director at Immatics Biotechnologies GmbH, mtm laboratories AG, and Sovicell GmbH, and a Non-Executive Director at Oxford Immunotec Ltd.
He also served as a Director at Implanet SA from 2007 to 2016.
Additionally, he has experience as a Director-Supervisory Board at Ambu Innovation GmbH, and as a Member-Supervisory Board at Definiens AG and Genticel SA. Dr. Strohmenger obtained his graduate and doctorate degrees from Ludwig-Maximilians-Universität München.
His current job(s) include Non-Executive Director at Quanta Dialysis Technologies Ltd.
and Director at AMBOSS GmbH.
Postes actifs de Rainer Strohmenger
| Sociétés | Poste | Début |
|---|---|---|
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/12/1997 |
Quanta Dialysis Technologies Ltd.
 Quanta Dialysis Technologies Ltd. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom. | Directeur/Membre du Conseil | - |
AMBOSS GmbH
 AMBOSS GmbH Miscellaneous Commercial ServicesCommercial Services AMBOSS GmbH owns and operates a web based platform for training physicians. It specializes in medicine, medical knowledge, health, medical students, e-learning, and clinical decision support. The company was founded by Kenan Hasan, Madjid Salimi and Sievert Weiss in November 2011 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | - |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Directeur/Membre du Conseil | 25/08/2020 |
Anciens postes connus de Rainer Strohmenger
| Sociétés | Poste | Fin |
|---|---|---|
| IMPLANET SA | Directeur/Membre du Conseil | 24/03/2016 |
| OXFORD IMMUNOTEC GLOBAL PLC | Directeur/Membre du Conseil | 21/11/2013 |
Oxford Immunotec Ltd.
 Oxford Immunotec Ltd. Medical SpecialtiesHealth Technology Oxford Immunotec Ltd. operates as a medical diagnostic company. It develops and sells medical diagnostic products. The company was founded by Peter Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom. | Directeur/Membre du Conseil | 02/10/2013 |
mtm laboratories AG
 mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Directeur/Membre du Conseil | - |
Definiens AG
 Definiens AG Packaged SoftwareTechnology Services Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany. | Directeur/Membre du Conseil | - |
Formation de Rainer Strohmenger
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMPLANET SA | Health Technology |
| Entreprise privées | 12 |
|---|---|
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
Oxford Immunotec Ltd.
Oxford Immunotec Ltd. Medical SpecialtiesHealth Technology Oxford Immunotec Ltd. operates as a medical diagnostic company. It develops and sells medical diagnostic products. The company was founded by Peter Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Ambu Innovation GmbH
 Ambu Innovation GmbH Medical SpecialtiesHealth Technology Ambu Innovation GmbH engages in the development and distribution of single-use and light-weight robotically-assisted high definition endoscopy products in the field of gastroenterology and gastro-intestinal surgery. Its products include invendoscope SC210, invendo ScopeController, and invendo SPU E210. The company was founded in 1992 and is headquartered in Kissing, Germany. | Health Technology |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Health Technology |
Oxford Immunotec Global Ltd.
 Oxford Immunotec Global Ltd. Medical SpecialtiesHealth Technology Oxford Immunotec Global Ltd. operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Sovicell GmbH
 Sovicell GmbH Pharmaceuticals: MajorHealth Technology Sovicell GmbH provides drug discovery services. It offers ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) to obtain pharmacokinetic data about their drug candidates or other test substances. The firm's products include plasma protein binding, brain tissue binding, brain-to-plasma distribution, microsomal binding and intestinal absorption. The company was founded in 1994 and is headquartered in Leipzig, Germany. | Health Technology |
Quanta Dialysis Technologies Ltd.
Quanta Dialysis Technologies Ltd. Medical SpecialtiesHealth Technology Quanta Dialysis Technologies Ltd. develops haemodialysis systems. The firm's SC+ is a performance, portable, compact haemodialysis system providing clinical efficacy utilising flow rates typically used on traditional machines. It offers SelfCare+, a haemodialysis machine for dialysis patients to control their disease and determine the treatment regime and care. The company was founded by Clive Henrey Buckberry, John Eric Milad and Martin Johnson in 2008 and is headquartered in Alcester, the United Kingdom. | Health Technology |
Definiens AG
Definiens AG Packaged SoftwareTechnology Services Definiens AG is a holding company, which engages in the development and market of biomedical imaging and data analysis software solutions. The firm specializes in the design and manufacture of imaging software suites for drug discovery, development, and diagnostics applications. It engages in the custom image analysis projects for the biopharmaceutical industry, spanning drug discovery, translational research, and clinical research. It offers image analysis processing, integration and deployment, planning, and consulting services. The company was founded by Gerd Binnig in 1994 and is headquartered in Munich, Germany. | Technology Services |
AMBOSS GmbH
AMBOSS GmbH Miscellaneous Commercial ServicesCommercial Services AMBOSS GmbH owns and operates a web based platform for training physicians. It specializes in medicine, medical knowledge, health, medical students, e-learning, and clinical decision support. The company was founded by Kenan Hasan, Madjid Salimi and Sievert Weiss in November 2011 and is headquartered in Berlin, Germany. | Commercial Services |
mtm laboratories AG
mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Health Technology |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
